Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus

Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate

WACKER expands production capacity for biopharmaceuticals in San Diego

Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry

WACKER to exhibit new adhesive, medical solutions at MD&M West

Wacker Biotech partners with Caeregen Therapeutics on regenerative treatment for vision loss

As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands

Wacker acquires Spain-based biotech firm ADL BioPharma

The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters

Wacker to expand mRNA-based actives capacity at Halle, Germany

Company is investing more than €100 million in the expansion of the Halle site

Wacker to build biotechnology center in Munich

The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements

Wacker, CordenPharma to produce mRNA vaccines for Germany

Both companies have been selected for stand-by production by German government

Wacker and Biosyntia to develop production process for sustainable biotin

The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative